ClinicalTrials.gg
Not yet recruitingNCT06836115Updated Feb 20, 2025

Reading and Stuttering

An observational study in Dyslexia, sponsored by Wafaa Helmy Abdelhakeem. Not yet recruiting. Open to participants aged 9 Years to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by Wafaa Helmy Abdelhakeem · Observational

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
200
Ages
9 Years to 10 Years
Sex
All
01

Study summary

Dyslexia is a common neurodevelopmental condition, which manifests itself in the form of reading difficulties and occurs in 7-10% of the population (Peterson \& Pennington, 2012).

As for dyslexia, it is one of the most common learning disorders and the most common cause of difficulties with reading, writing, and spelling. The global prevalence of dyslexia is estimated to be between 5% and 10% of the population, but it may be as high as 17% (Sprenger-Charolles et al., 2011). Stuttering is a speech disorder characterized by involuntary, audible, or silent repetitions or prolongations of sounds or syllables, along with disturbances in the fluency of verbal phrases.Stuttering and dyslexia are two processing deficits that have an impact on a person's social and academic lives, especially as they usually affect the pediatric population more than adults. Even though they affect different domains, they have similar characteristics in their pathogenesis, epidemiology, and impact on life (Algaidy et al., 2023). The aim of the study will be to identify the prevelance of dyslexia in developmental stuttering.

02

Conditions studied

  • Dyslexia

Browse trials for

03

In context

Dyslexia

127 studies on the registry are indexed under Dyslexia; 27 are open to participants now.

This study's planned enrollment of 200 is above the median of 90 across 20 observational studies indexed under Dyslexia.

Browse Dyslexia studies →

Lead sponsor

This is the only study on the registry with Wafaa Helmy Abdelhakeem as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

This study will include 200 patients. Subjects will be divided into two groups, group A will include with 100 participants with developmental stuttering and group B will include 100 participants with normal fluency speech.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • children with stuttering

Exclusion criteria

Exclusion Criteria:

  • children with delayed language development
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • group A

    will include with 100 participants with developmental stuttering

  • group B

    will include 100 participants with normal fluency speech.

06

What researchers measure

Primary outcomes

  1. 4- Arabic Reading Test

    arabic reading test in scores

    Time frame: baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2025; primary completion for Apr 2025, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2025
First posted
Feb 20, 2025
StartEst.
Feb 25, 2025
Primary completionEst.
Apr 25, 2025
CompletionEst.
May 1, 2025
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06836115
Lead sponsor
Wafaa Helmy Abdelhakeem
Responsible party
Wafaa Helmy Abdelhakeem (doctor, Minia University) — Sponsor-investigator
First posted
Feb 20, 2025
Start date
Feb 25, 2025 (estimated)
Primary completion
Apr 25, 2025 (estimated)
Completion
May 1, 2025 (estimated)
Last update
Feb 20, 2025

Study contacts

Wafaa Helmy Abd El-hakeem
Contact
wafaa.helmy@edu.mu.eg
01091813874

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion